A Pragmatic Trial of the Consult for Addiction Treatment & Care in

Status Completed

Clinical Trial Summary

This pragmatic clinical trial seeks to evaluate the effectiveness of the Consult for Addiction Treatment and Care in Hospitals (CATCH) intervention as a strategy for engaging patients with Opiod Use Disorder (OUD) in addiction treatment.

Clinical Trial Description

The overarching objective of our study is to evaluate the effectiveness of CATCH as a strategy for engaging patients with OUD in MAT. A pragmatic trial at 6 hospitals, conducted in collaboration with the New York City Health and Hospitals system (H+H) and the New York City Department of Health and Mental Hygiene (DOHMH), will study the CATCH intervention in real-world settings and at scale. Guided by the RE-AIM evaluation framework, this hybrid effectiveness-implementation study (Type 1) focuses primarily on effectiveness, but also measures implementation outcomes to inform the intervention's adoption and sustainability. A rigorous stepped-wedge cluster randomized trial design determines the impact of CATCH on opioid treatment outcomes in comparison to usual care for a control period, followed by a 12-month intervention period and a maintenance period, and utilizes existing administrative data to evaluate outcomes. Aim 1 (primary aim) is to evaluate the effectiveness of CATCH in increasing post-discharge initiation and engagement in MAT, defined respectively as receiving outpatient MAT within 14 days of discharge, and having at least 2 additional MAT visits in the first month. Aim 2 is to assess the effectiveness of CATCH for increasing treatment retention, defined as continuous receipt of MAT for 6 months. Aim 3 is to compare the frequency of acute care utilization and overdose deaths, and their associated costs, among patients with OUD who are hospitalized during the CATCH period versus usual care. Aim 4 is to evaluate implementation outcomes at CATCH sites using a mixed methods approach to assess the intervention's Reach (proportion of eligible patients reached); Adoption (utilization by medical staff); and Implementation fidelity (barriers to delivering high-quality MAT). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03611335
Study type	Observational [Patient Registry]
Source	NYU Langone Health
Contact
Status	Completed
Phase
Start date	December 7, 2018
Completion date	March 20, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03675386` - Reducing Opioid Use for Chronic Pain Patients Following Surgery	N/A
Completed	`NCT02593474` - Medication-Assisted Treatment for Youth With Substance Use Disorders	Phase 1
Completed	`NCT02282306` - Phone Interview to Prevent Recurring Opioid Overdoses	N/A
Completed	`NCT02294253` - Buprenorphine/Naloxone Stabilization and Induction Onto Injection Naltrexone	Phase 2/Phase 3
Completed	`NCT01592461` - Starting Treatment With Agonist Replacement Therapies Follow-up Study	N/A
Terminated	`NCT00768482` - A Bioavailability and Safety Study of Probuphine Versus Sublingual Buprenorphine in Patients With Opioid Dependence	Phase 3
Completed	`NCT01741350` - Testing a Community-Friendly Risk Reduction Intervention for Injection Drug Users	N/A
Terminated	`NCT04121546` - Collaborative Care for Opioid Dependence And Pain Pilot Study	N/A
Withdrawn	`NCT03368794` - Naloxone to TReatment Entry in the Emergency Setting	N/A
Completed	`NCT03447743` - Re-entry XR-NTX for Rural Individuals With Opioid Use Disorder	Early Phase 1
Completed	`NCT04464421` - SMART Effectiveness Trial	N/A
Recruiting	`NCT04189523` - Does Early Administration of Ultrasound Guided Regional Anesthesia for Long Bone Fractures Effect Long Term Patient Opioid Usage	N/A
Completed	`NCT03305666` - Trial of Injected Liposomal Bupivacaine vs Bupivacaine Infusion After Surgical Stabilization of Rib Fractures	Phase 4
Recruiting	`NCT04003948` - Preliminary Efficacy and Safety of Ibogaine in the Treatment of Methadone Detoxification	Phase 2
Not yet recruiting	`NCT03813095` - Exploratory Dose Ranging Study Assessing APH-1501 for the Treatment of Opioid Addiction	Phase 2
Terminated	`NCT02935101` - Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants	Phase 2
Completed	`NCT01895270` - Improving Buprenorphine Detoxification Outcomes With Isradipine	Phase 1/Phase 2
Completed	`NCT01717963` - Naltrexone vs Buprenorphine-Naloxone for Opioid Dependence in Norway	Phase 3
Completed	`NCT01425060` - Improving Effective Contraceptive Use Among Opioid-maintained Women	Phase 1
Completed	`NCT02324725` - Biomarkers of Injectable Extended Release Naltrexone Treatment	Phase 4

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

A Pragmatic Trial of the Consult for Addiction Treatment and Care in Hospitals (CATCH) Model for Engaging Patients in Opioid Use Disorder Treatment — CATCH

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms